StiRx is a biotech company developing precision biologics, including monoclonal antibodies, bispecific antibodies, and vaccines, to prevent sexually transmitted infections in high-risk populations. The company's pipeline targets gonorrhea and chlamydia with long-acting immune protection designed to reduce transmission and antibiotic resistance. StiRx focuses on proactive prevention rather than reactive treatment for individuals with persistent structural exposure to STIs.
Funding
Funding not disclosed
Founders
Product
Problem
Sexually transmitted infections remain a recurring and costly burden in populations with persistent exposure, where short-acting therapies and rising antimicrobial resistance limit the effectiveness of today's treatment-centric approach. In these high-incidence networks, repeat infections and antibiotic resistance hotspots create an urgent need for durable prevention options that are largely unavailable.
Solution
StiRx addresses this prevention gap by developing engineered biologics, including monoclonal antibodies, bispecific antibodies, and vaccines designed for long-acting protection at the point of infection. The company's strategy is to translate exposure risk into durable immune protection, reducing transmission and downstream antibiotic pressure in high-risk populations. StiRx focuses on preventing repeat infection, lowering downstream treatment costs, and providing individuals a simple, reliable way to manage ongoing risk. The pipeline currently targets gonorrhea and chlamydia, with other STI treatments being explored.
Target Audience
Primary customers are healthcare systems, public health programs, and clinicians serving high-risk populations with persistent structural exposure to sexually transmitted infections, including networks with high STI incidence and repeat infection rates.
Features
- Pipeline of preventive biologics including monoclonal antibodies, bispecific antibodies, and vaccines for STI prevention
- Lead programs targeting Neisseria gonorrhoeae and Chlamydia trachomatis, with additional STI indications under exploration
- Novel gonorrhea vaccine approach, presented at the International Pathogenic Neisseria Conference (IPNC 2026)
- Focus on long-acting immune protection designed to reduce repeat infections and antimicrobial resistance pressure
- Research published in Current Opinion in Infectious Diseases analyzing treatment paradigms for drug-resistant gonorrhea